• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 30, 2017

View Archived Issues

It's déjà vu all over again as Eli Lilly exits Adocia diabetes alliance

Shares in Adocia SA (PARIS:ADOC) dropped more than 30 percent Friday, falling €12.67 (US$13.55) to close at €27.60 (US$29.51), on news that Eli Lilly and Co. was once again exiting an alliance in type 1 and type 2 diabetes. Read More

Bench Press: BioWorld looks at translational medicine

The cell surface protein CD99 is expressed on cancer stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS), and it could serve as both a marker and a therapeutic target in those disorders. Read More

Nitric oxide disqualified? Analyst says Novan acne bid lives despite data mix

Novan Inc.'s effort to market the first-ever topical nitric oxide (NO) macromolecule – one that would be the first new chemical entity for acne in decades – stumbled on word that topical SB2014 met with success in one phase III trial but only a partial win in the second, identical study. Read More

Jounce bounce: Celgene deal a lure as upsized IPO tops $100M

Jounce Therapeutics Inc. rose to the head of the pack of early 2017 biopharma IPOs by pricing an upsized offering of 6.365 million shares at $16 apiece, above the intended range of $13 to $15, for proceeds of $101.8 million, up from its proposed $75 million raise. Read More

Chimeras give insights into embryology and transplantation

Basic developmental biology and organ transplantation both got a boost this week, with two groups reporting progress in generating chimeras, and generating medically useful cell types using those chimeras. Read More

India battles growing antibiotic resistance, noncompliant sales

NEW DELHI –In the wake of the death of a U.S. woman who had been infected with a drug-resistant bug in India, the country's drug regulator has ordered all companies involved in the drug supply chain system to strictly follow the country's guidelines in the Drugs and Cosmetics Act on the sale of medicines. Read More

Financings

Biscayne Neurotherapeutics Inc., of Miami, completed a $3 million series B financing. The financing was led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners. Existing Biscayne investors and new private investors also participated. Read More

Earnings

Abbvie Inc., of North Chicago, posted fourth quarter 2016 net product revenues of $6.78 billion, down about 2 percent from the fourth quarter of 2015 and below analysts' average estimate of $6.91 billion, according to Thomson Reuters I/B/E/S/. Read More

Other news to note

Pfizer Inc., of New York, said that the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending Xeljanz (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis (RA). Read More

Appointments and advancements

Anaptysbio Inc., of San Diego, appointed Dominic Piscitelli chief financial officer. Read More

In the clinic

Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan, reported that an open-label, single-arm phase III trial of FP-001 LMIS (leuprolide mesylate) 50 mg in patients with advanced prostate carcinoma achieved its primary efficacy endpoint in 97 percent of the study's participants. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe